Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

E. Dorman, Susan; Nahid, Payam; V. Kurbatova, Ekaterina; Phillips, Patrick; Bryant, Kia; E. Dooley, Kelly; Engle, Melissa; Goldberg, Stefan; Phan, Ha; Hakim, James; L. Johnson, John; Lourens, Madeleine; Martinson, Neil; Muzanyi, Grace; Narunsky, Kim; Nerette, Sandy; Viet Nhung, Nguyen; Pham, Thuong; Pierre, Samuel; Purfield, Anne; Samaneka, Wadzanai; M. Savić, Radojka; Sanne, Ian; Scott, Nigel; Shenje, Justin; Sizemore, Erin; Vernon, Andrew; Waja, Ziyaad; Weiner, Marc; Swindells, Susan; E. Chaisson, Richard

doi:10.1056/nejmoa2033400

Public

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

Published in New England Journal of Medicine • May 5, 2021

Authors:

Susan E. Dorman

Payam Nahid

Ekaterina V. Kurbatova

Abstract

BACKGROUND: Rifapentine-based regimens have potent antimycobacterial activity that may allow for a shorter course in patients with drug-susceptible pulmonary tuberculosis. METHODS: In an open-label, phase 3, randomized, controlled trial involving persons with newly diagnosed pulmonary tuberculosis f...

Subject

Rifapentine

Moxifloxacin

Tuberculosis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!